Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
LGND:NASDAQ
Ligand Pharmaceuticals Inc
227,44 US$
-0,88%
(-2,01) 1D
227,44 US$
0,00% (0,00)
After hours
Closed: 1 may, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LGND...
Açın
229,87 US$
High
236,22 US$
Low
226,46 US$
Mkt. cap
4,56 mlrd
Avg. vol.
249,88K
Volume
235,41K
P/E ratio
37,09
52-wk high
238,31 US$
52-wk low
98,89 US$
EPS
6,13 US$
Beta
1,06
Shares outstanding
20,04 mln
No. of employees
47
News stories
From sources across the web
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
Foundedsen 1987
HeadquartersJupiter, Florida, Amerika Birləşmiş Ştatları
SectorPharmaceutical industry
Websiteligand.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
45,33 mln
47,63 mln
115,46 mln
59,67 mln
Cost of goods sold
54,93 mln
9,47 mln
24,82 mln
6,50 mln
Cost of revenue
54,93 mln
9,47 mln
24,82 mln
6,50 mln
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18,80 mln
20,18 mln
28,45 mln
25,03 mln
Operating expense
27,06 mln
28,43 mln
36,54 mln
33,12 mln
Total operating expenses
81,99 mln
37,91 mln
61,36 mln
39,63 mln
Operating income
-36,66 mln
9,72 mln
54,10 mln
20,04 mln
Other non operating income
-2,06 mln
96,00K
390,00K
1,48 mln
EBT including unusual items
-50,18 mln
11,22 mln
141,14 mln
56,78 mln
EBT excluding unusual items
-37,81 mln
10,28 mln
57,45 mln
116,80 mln
Income tax expense
-7,73 mln
6,38 mln
23,86 mln
12,00 mln
Effective tax rate
15,40%
56,81%
16,91%
21,13%
Other operating expenses
-
-
-
-
Net income
-42,45 mln
4,85 mln
117,27 mln
44,78 mln
Net profit margin
-93,64%
10,18%
101,57%
75,06%
Earnings per share
1,33
1,60
3,09
2,02
Interest and investment income
1,77 mln
1,62 mln
3,87 mln
6,39 mln
Interest expense
-867,00K
-1,15 mln
-910,00K
-1,78 mln
Net interest expenses
904,00K
468,00K
2,96 mln
4,61 mln
Depreciation and amortization charges
-
-
-
-
EBITDA
-28,35 mln
17,82 mln
63,26 mln
28,25 mln
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer